| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/35-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | PKR2; PRKAR2 |
| WB Predicted band size | 46 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human PRKAR2A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于PRKAR2A抗体的3篇参考文献的简要信息：
1. **"Characterization of PRKAR2A expression in cardiac tissues using a novel monoclonal antibody"**
- **作者**: Smith J, et al.
- **摘要**: 本研究开发了一种特异性识别PRKAR2A的单克隆抗体，并通过免疫组化和Western blot验证其在人类心肌组织中的表达，发现其在心力衰竭患者中表达显著下调，提示其与心脏功能调控相关。
2. **"PRKAR2A antibody-based profiling in adrenal tumors reveals diagnostic potential"**
- **作者**: Lee H, et al.
- **摘要**: 利用PRKAR2A多克隆抗体对肾上腺皮质肿瘤样本进行免疫染色，发现PRKAR2A在良性腺瘤中高表达，而在恶性肿瘤中缺失，表明其可能作为区分肿瘤性质的生物标志物。
3. **"Role of PRKAR2A in cAMP signaling: Insights from siRNA and antibody-mediated inhibition"**
- **作者**: Garcia R, et al.
- **摘要**: 通过PRKAR2A抗体阻断实验结合siRNA技术，揭示PRKAR2A在cAMP/PKA信号通路中的调控作用，发现其缺失会增强细胞增殖能力，为肿瘤靶向治疗提供新思路。
(注：上述文献为示例，实际引用需根据具体数据库检索结果调整。)
The PRKAR2A antibody is a crucial tool for studying the regulatory subunit RIIα of protein kinase A (PKA), a central enzyme in cAMP-mediated signaling pathways. PRKAR2A (cAMP-dependent protein kinase type II-alpha regulatory subunit) plays a key role in anchoring PKA to specific cellular compartments via A-kinase anchoring proteins (AKAPs), ensuring localized phosphorylation events that regulate diverse processes, including metabolism, gene expression, and cell proliferation. This antibody is widely used in Western blotting, immunohistochemistry, and immunofluorescence to detect PRKAR2A expression, which is ubiquitously present in tissues but shows elevated levels in the brain, heart, and skeletal muscle.
Research utilizing PRKAR2A antibodies has elucidated its involvement in diseases such as cardiovascular disorders, endocrine tumors, and Carney complex—a genetic condition linked to PRKAR1A mutations, where PRKAR2A expression may compensate for dysfunctional regulatory subunits. Additionally, PRKAR2A dysregulation has been implicated in cancer progression, with studies highlighting its role in modulating cell cycle checkpoints and apoptosis. Commercially available PRKAR2A antibodies are typically raised in rabbits or mice, targeting specific epitopes within the protein's N-terminal or cAMP-binding domains. Validation includes reactivity checks in knockout models or siRNA-treated cells to ensure specificity. Researchers must optimize protocols for tissue types and fixation methods, as post-translational modifications (e.g., phosphorylation) or isoform cross-reactivity (e.g., PRKAR2B) may affect results. This antibody remains vital for dissecting cAMP-PKA signaling mechanisms in health and disease.
×
